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Adenosine kinase (ADK) is considered to be the key regulator of the brain’s endogenous anticonvulsant,
adenosine. In adult brain, ADK is primarily expressed in a subpopulation of astrocytes and striking upregulation
of ADK in these cells has been associated with astrogliosis after kainic acid-induced status epilepticus (KASE) in
the kainic acid mouse model of temporal lobe epilepsy. To investigate the causal relationship between KASE-
induced astrogliosis, upregulation of ADK and seizure activity, we have developed a novel mouse model [the
Adktm1/-Tg(UbiAdk) mouse] lacking the endogenous astrocytic enzyme due to a targeted disruption of the
endogenous gene, but containing an Adk transgene under the control of a human ubiquitin promoter. Mutant
Adktm1/-Tg(UbiAdk) mice were characterized by increased brain ADK activity and constitutive overexpres-
sion of transgenic ADK throughout the brain, with particularly high levels in hippocampal pyramidal neurons.
This ADK overexpression was associated with increased baseline levels of locomotion. Most importantly, two-
thirds of the mutant mice analysed exhibited spontaneous seizure activity in the hippocampus and cortex. This
was the direct consequence of transgene expression, since this seizure activity could be prevented by systemic
application of the ADK inhibitor 5-iodotubercidin. Intrahippocampal injection of kainate in the mutant mice
resulted in astrogliosis to the same extent as that observed in wild-type mice despite the absence of endogenous
astrocytic ADK. Therefore, KASE-induced upregulation of endogenous ADK in wild-type mice is a consequence
of astrogliosis. However, seizures in kainic acid-injected mutants displayed increased intra-ictal spike frequency
compared with wild-type mice, indicating that, once epilepsy is established, increased levels of ADK aggravate
seizure severity. We therefore conclude that therapeutic strategies that augment the adenosine system after
astrogliosis-induced upregulation of ADK constitute a neurochemical rationale for the prevention of seizures in
epilepsy.
Keywords: adenosine; adenosine kinase; epilepsy; astrogliosis; transgenic mice
Abbreviations: A1R = adenosine A1 receptor; ADK = adenosine kinase; DPCPX = 8-cyclopentyl-1,3-dipropyl-xanthine;
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Introduction
The purine ribonucleoside adenosine is an important modu-
lator of central nervous system functions (Dunwiddie and
Masino, 2001), exerting primarily inhibitory effects on neur-
onal activity. Adenosine receptor antagonists, such as caffeine,
display stimulant properties (Fredholm et al., 1999), while
activation of the adenosine A1 receptor (A1R) has potent
inhibitory effects on neuronal activity (Fredholm, 1997). In
humans, microdialysis studies demonstrated a release of
adenosine during seizure activity and adenosine was proposed
to be a natural mediator of seizure arrest and postictal
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refractoriness (During and Spencer, 1992). Systemic admin-
istration of selective A1R agonists or intracerebral grafting of
encapsulated adenosine-releasing cells suppresses seizure
activity in various rodent models of epilepsy (Dunwiddie,
1999; Dunwiddie and Masino, 2001; Boison, 2005). Of
particular relevance is the recent finding that activation of
A1Rs leads to the suppression of seizures in the mouse kainate
model of pharmacoresistant temporal lobe epilepsy, thus
pointing to adenosine as a potential therapeutic advance
compared with conventional antiepileptic drugs (Gouder
et al., 2003). Due to the therapeutic potential of adenosine
in the treatment of pharmacoresistant epilepsy, the study of
mechanisms underlying adenosinergic neuromodulation in
epilepsy is an important issue.
On the basis of its low KM for adenosine, adenosine kinase
(ADK, EC 2.7.1.20) is considered to be the key enzyme for the
regulation of brain adenosine levels (Mathews et al., 1998).
This concept is supported by a number of studies: (i) phar-
macological inhibition of ADK increases A1R-mediated pre-
synaptic inhibition in hippocampal slices (Pak et al., 1994);
(ii) inhibition of adenosine deaminase has little or no effect
on the extracellular adenosine concentration (Pak et al., 1994;
Zhu and Krnjevic, 1994; Huber et al., 2001); and (iii) in the
brain there is a high flux rate in the futile cycle of adenosine
to AMP involving ADK and 50-nucleotidase (Bontemps
et al., 1983).
Normally, brain activity is under the influence of tonic
adenosinergic inhibition. This results from low basal ADK
levels produced by a subpopulation of astrocytes that are
evenly distributed throughout the whole brain (Gouder et al.,
2004). However, in the mouse kainate model of temporal lobe
epilepsy, upregulation of endogenous astrocytic ADK is
observed in parallel with ongoing astrogliosis and seizure
activity after kainic acid (KA)-induced status epilepticus
(KASE) (Gouder et al., 2004). To analyse the specific role
of ADK in astrogliosis and seizure activity, we have created
a novel mouse mutant in which the endogenous expression of
ADK in astrocytes is abolished and replaced by constitutive
transgene-driven overexpression of ADK.
Methods
Generation of adenosine kinase
transgenic mice
Adktm1/ mice were created by homologous recombination of the
Adk gene in embryonic stem cells as described (Boison et al., 2002).
For the generation of Adk transgenic animals, an 1865 bp full-length
Adk cDNA (Gouder et al., 2004), homologous to the short iso-
form (38.7 kDa) of Adk described in humans (McNally et al.,
1997), was cloned into a transgene expression vector containing a
human ubiquitin promoter and the splice and poly(A) sequences of
SV40 (Schorpp et al., 1996). In a last cloning step, the Adk expression
cassette was flanked with loxP sites. The linearized vector was puri-
fied and injected into the pronucleus of fertilized oocytes derived
from Adktm1+/ matings. Three independent UbiAdk transgenic
lines were established and maintained on a mixed B6,129P3
background.
Animals
The introduction of the UbiAdk transgene into the Adktm1/ back-
ground rescued the lethal phenotype related to ADK deficiency
(Boison et al., 2002). Adktm1/-transgenic (Tg)(UbiAdk) mice
from two of the three lines (Tg888 and Tg890) were fertile and
did not show overt abnormality. Male Adktm1/-Tg(UbiAdk)
and wild-type mice, aged 8–9 weeks, were used for all in vivo analyses.
They were reared in individual cages with food and water ad libitum
under standard 12-h light/12-h dark cycle conditions (light on at
07:00 h). All animal procedures were conducted in accordance with
the regulations of the local animal welfare authority. All efforts were
made to minimize animal suffering and to reduce the number of
animals used for experimentation.
Genotyping
The endogenous Adk locus was analysed in individual PCR reactions
containing a mix of the three primers o107, o108 and o109 (Fedele
et al., 2004). PCR primers used for the detection of the Adk transgene
were o141, 50-GGA AGC TGC CAC TTT TGC TAG AGA GC-30, and
o142, 50-GGA ACG CTC AGG ATG TGG TCA CTG C-30. The
combination of primers o107 with o108 gave rise to 640-bp products
(indicative of a wild-type Adk allele), whereas the combination of
primers o107 with o109 gave rise to 840-bp products (indicative
of the Adk knockout allele). The combination of primers o141
and o142 gave rise to 420-bp products indicative of the transgene.
The zygosity of the transgene was determined in a TaqMan real-
time PCR analysis as follows. Individual TaqMan PCR reactions
were performed in duplicate with the ABI PRISM 7700 Sequence
Detection System (Applied Biosystems, Rotkreuz, Switzerland) as
described previously (Zumsteg and Boison, 2002). For the quanti-
fication of the transgene, the following transgene specific primers
were used: tg-fwd (50-ACT TGT GCT GCG TGC ATC A-30), tg-rev
(50-TAA CAA TTG GCG GCA GCA A-30), and a 50-FAM- and 30-
TAMRA-labelled fluorogenic TaqMan probe (50-FAM-CAA CGA
GGG ACC TGT TGC CAC CA-30-TAMRA). Amplification of the
Adk knockout allele was used as an internal reference [two allele
copies in Adktm1/-Tg(UbiAdk) mice]. The knockout-specific pri-
mers and probes were specific for the EGFP-containing gene inser-
tion cassette: Adk-ko-fwd (50-GCC GTC TTT TGG CAA TGT G-30,
Adk-ko-rev (50-CCC CTA GGA ATG CTC GTC AA-30), and a
50-FAM- and 30-TAMRA-labelled fluorogenic TaqMan probe
(50-FAM-CCG GGA AAC CTG GCC CTG TCT T-30-TAMRA).
After completion of the PCR reactions, a threshold of the fluores-
cence intensity was set within the linear phase of the amplifications.
The cycle number (CT) in which this threshold was crossed by the
active reporter fluorescence was determined. The zygosity was
calculated by comparison of the CT values of the respective tgUbi-
Adk-allele with the CT values from the reference gene. All
Adktm1/-Tg(UbiAdk) mice used in this study were homozygous
for the transgenic locus.
Western blot analysis
Aqueous extracts derived from whole brain, liver, lung, kidney and
heart from adult Adktm1/-Tg(UbiAdk) (n = 3) and wild-type mice
(n = 3) were prepared as described (7). Supernatants, each containing
15 mg protein, were separated on a sodium dodecyl sulphate/10%
polyacrylamide gel and blotted onto a nitrocellulose membrane.
The blots were probed with a polyclonal rabbit antiserum against
ADK and processed as described (Boison et al., 2002; Gouder et al.,
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2004). Note that, in wild-type brain, only the short 38.7 kDa isoform
of ADK is expressed, whereas in the other organs both isoforms are
present. Because we used the short isoform of ADK for the transgenic
rescue of ADK deficiency, the overexpression of ADK in Adktm1/-
Tg(UbiAdk) mice involves only this isoform.
In vitro electrophysiology
Acute coronal slices (300 mm) containing the hippocampus were
obtained from P13-P20 Adktm1/-Tg(UbiAdk) and wild-type mice.
They were incubated for 30 min in oxygenated (95% O2, 5% CO2)
artificial cerebrospinal fluid solution at 34C containing (mM) 124
NaCl, 2.5 KCl, 1.3MgCl2, 26 NaHCO3, 1.25 NaH2PO4, 2.5 CaCl2 and
11 glucose, and maintained at room temperature for at least 1 h
before they were transferred to a superfusing chamber. Whole-cell
voltage-clamp recordings of CA3 pyramidal neurons were performed
at room temperature in response tomossy fibre stimulation delivered
via a bipolar tungsten stimulating electrode placed in the stratum
lucidum (0.1 ms, 1–10 V, at 20-s interstimulus intervals). Voltage-
clamp recordings were obtained with 3–5 MV patch pipettes con-
taining (mM) 130 K+ gluconate, 10 HEPES, 1 EGTA, 5 NaCl, 5 ATP-
Mg and 0.5 GTP-Na. Excitatory postsynaptic currents (EPSCs) were
recorded at a holding potential of 70 mV in the presence of
picrotoxin (100 mM) and a subsaturating concentration of
NBQX (1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo[f]quinoxaline-
7-sulphonamide) (0.25 mM) to prevent picrotoxin-induced seizure
activity in slices from Adktm1/-Tg(UbiAdk) mice. 8-Cyclopentyl-
1,3-dipropylxanthine (DPCPX) or 50-iodotubercidin (ITU) was
added at final concentrations of 200 nM or 5 mM, respectively. At
the end of all experiments, (2S,10S,20S)-2-(carboxycyclopropyl) gly-
cine (LCCG1) (10 mM) was added to confirm that EPSCs originated
in mossy fibres (Moore et al., 2003). Experiments were used only if
the LCCG1-mediated inhibition was at least 70% of EPSC peak
amplitude. Signals were recorded with an Axopatch 200B (Axon
Instruments, Foster City, CA, USA) amplifier and digitized at
5 kHz. Data were processed using IgorPro software (Wavemetrics,
Lake Oswego, OR, USA). Data were discarded if access resistance
varied by more than 20% during the course of the experiment.
Picrotoxin, NBQX, DPCPX and LCCG1 came from Tocris Cookson
(Bristol, UK) and were prepared daily from concentrated stock
solutions.
Circadian locomotor activity
Mutant and wild-type mice were transferred to the testing room and
allowed to adapt to a reversed 12-h light/dark cycle (light on at 20:00
h) for at least 10 days before the experiment. Spontaneous locomotor
activity was recorded continuously in automated individual circular
arenas (Imetronic, Pessac, France) over a period of 4 days. Data were
collected during the last 3 days for statistical analysis. After comple-
tion of the experiment, mice were killed by decapitation for ADK
activity measurement.
Electroencephalographic recordings
Adktm1/-Tg(UbiAdk) (n = 24) and wild-type (n = 9) mice were
tested for spontaneous seizure activity. The procedure of electrode
implantation was as previously described (Gouder et al., 2003). In
addition to the standard bipolar electrode in the dorsal hippocam-
pus, 14 out of the 24 mice were equipped with two monopolar
electrodes placed at the cortical surface for simultaneous hippocam-
pal and cortical EEG recordings. The day after surgery, mice were
familiarized with the recording chamber and EEG activities were
recorded as described previously (Gouder et al., 2003). A further
series of 6 Adktm1/-Tg(UbiAdk) mice and six wild-type mice were
stereotactically injected with a solution of 1 nmol of KA into the right
dorsal hippocampus as described (Gouder et al., 2004). All KA-
injected mice were implanted with a bipolar electrode into the
right dorsal hippocampus and a monopolar reference electrode
over the cerebellum. They were subjected to EEG recordings 4–6
weeks after KA injection.
Histological analysis
Adult Adktm1/-Tg(UbiAdk) and wild-type mice were perfused
transcardially with 4% paraformaldehyde and 15% saturated picric
acid solution in phosphate buffer (0.15 M, pH 7.4). The brains were
then postfixed in the same fixative at 4C for 6 h and cryoprotected in
10% dimethylsulphoxide in phosphate-buffered saline (v/v) before
being cut into 40 mm sagittal or coronal sections using a sliding
microtome. For the immunohistochemical detection of ADK,
brain sections were incubated overnight at 4C with primary anti-
ADK antiserum diluted 1 : 5000 in Tris–Triton, pH 7.4, containing
2% normal goat serum and 0.2% Triton X-100. The sections were
then washed 3 · 10 min in Tris-buffered saline (TBS) at pH 7.4,
incubated for 30 min with biotinylated goat anti-rabbit antibody
diluted 1 : 300 in Tris–Triton, pH 7.4, containing 2% normal
goat serum, washed again three times in TBS then incubated for
20–30 min with an avidin : biotin enzyme complex (Vectastain
Elite Kit; Vector Laboratories, Burlingame, CA, USA). After washing
again three times with TBS, the tissue antigen was localized by
incubation with diaminobenzidine hydrochloride (Sigma,
St Louis, MO, USA), which acts as a chromogen. The sections
were then mounted on gelatin-coated slides, air-dried and cover-
slipped. The immunoperoxidase-stained sections were analysed with
a Zeiss AxioCam microscope (Zeiss, Jena, Germany) equipped with
bright-field microscopy, using a high-resolution digital camera. KA-
induced astrogliosis was evaluated by immunofluorescence staining
with a monoclonal mouse antibody against the astrocytic marker
glial fibrillary acidic protein (GFAP) (MAB360; Chemicon Interna-
tional, Temecula, CA, USA) on coronal brain sections from wild type
and Adktm1/-Tg(UbiAdk) mice, 6 weeks after KA injection. GFAP
immunofluorescence staining was also performed on coronal sec-
tions from untreated control animals of both genotypes for com-
parison.
Adenosine kinase enzyme activity
Brain homogenates were purified and ADK activity was quantified
using an enzyme-linked bioluminescent assay (Gouder et al., 2004)
according to the following principle: an excess of adenosine, added to
the sample, is phosphorylated by ADK to AMP, which is then phos-
phorylated further to ATP by an excess of recombinant GTP : AMP
phosphotransferase (own production) and pyruvate kinase. The res-
ulting ATP is then quantified with a commercial luciferase assay kit
(ATP Bioluminescent Assay Kit; Sigma). ADK activity values,
expressed as the relative number of light units per time, were nor-
malized to endogenous lactate dehydrogenase (LDH) activity, which
was taken as an internal standard. LDH activity was determined with
a commercial assay kit according to the manufacturer’s protocol
(Roche, Rotkreuz, Switzerland). The assay was validated by plotting
a standard curve of different ratios of samples from wild-type mice
mixed with those from Adktm1/ mice.
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Results
Insertion of an Adk transgene provides
genetic rescue of lethal ADK-deficiency
To study the causal relationship between overexpression of
ADK, astrogliosis and seizure activity, we changed the expres-
sion of ADK from selected astrocytes to a widespread expres-
sion pattern encompassing both neurons and astrocytes. This
was accomplished by introducing an ubiquitously expressed
Adk transgene into an ADK-deficient host mouse line
(Adktm1/) (Boison et al., 2002). We constructed a trans-
gene (tgUbiAdk) of an Adk cDNA (Boison et al., 1999), cor-
responding to the short (38.7 kDa) brain-specific isoform of
the enzyme (McNally et al., 1997; Gouder et al., 2004), under
the control of the human ubiquitin promoter (Fig. 1A)
(Schorpp et al., 1996). The transgene was injected into pro-
nuclei of fertilized oocytes derived from Adktm1+/ matings.
Twenty-nine mice were obtained, of which three founders
carried the transgene on an Adktm1+/ background
(Adktm1+/-Tg(UbiAdk), Fig. 1B). These mice were then
bred with Adktm1+/ mice. Two of the three transgenic
lines (Tg888 and Tg890) gave rise to all six possible genotypes
(Fig. 1B), including Adktm1/-Tg(UbiAdk). Adktm1/-
Tg(UbiAdk) mice (m#3, Fig. 1C) were identified in an
Adk-specific PCR analysis by a characteristic 840 bp band
from the Adk knockout allele (m#2 in Fig. 1C as control),
a lack of the 640 bp band indicative of the wild-type allele
(m#1 in Fig. 1C as control), and the presence of a 420 bp band
(m#3 in Fig. 1C) from the UbiAdk transgene. The genotypes
were also verified in a transgene- and knockout-specific
TaqMan real-time PCR analysis (data not shown).
Overexpression of brain ADK in
Adktm1/-Tg(UbiAdk) mice
The expression of the tgUbiAdk transgene was examined by
Western blot analysis in various organs from adult
Adktm1/-Tg(UbiAdk) (line Tg888) and wild-type mice.
In wild-type mice, ADK was highly expressed in liver and
intermediate levels were observed in brain, lung and kidney,
and the weakest expression was found in the heart (Fig. 2A).
In Adktm1/-Tg(UbiAdk) mice, the highest expression of
ADK was detected in brain extracts, whereas the liver ADK
content was poorly reconstituted (Fig. 2A). ADK levels in
heart, kidney and lung of the mutants were similar to
those in wild-type mice. Remarkably, the rather low levels
of transgenic ADK expression in liver appeared to be sufficient
for phenotypic correction of the Adk/ fatty liver (data not
shown). We quantified ADK enzyme activity using an
enzyme-coupled bioluminescent assay in brain extracts
from mutant and wild-type mice and found that
Adktm1/-Tg(UbiAdk) mice displayed a 2.2-fold increase
in ADK activity compared with wild-type mice (P < 0.001,
median test) (Fig. 2B). In addition, we measured brain ADK
activity in threeAdktm1/-Tg(UbiAdk)mice from line Tg890
and observed a slight elevation (6%) compared with wild-type
Fig. 1 Generation of Adktm1/-Tg(UbiAdk) mice. (A) The short
isoform of mouse Adk-cDNA was inserted between a human
ubiquitin promoter (hUbi) and an SV40 poly(A) sequence (polyA).
The UbiAdk transgene (open boxes) was flanked by loxP sites (grey
triangles). (B) Transgenic founders, Adktm1+/-Tg(UbiAdk) mice,
which were heterozygous for both the transgene and the Adk
knockout, were backcrossed with Adktm1+/ mice. From these
backcrosses, offspring with six different genotypes were derived,
among them Adktm1/-Tg(UbiAdk) mice (m#3), which were
viable, like wild-type mice (Adk+/+) (m#1), and in contrast to
homozygous Adk knockout mice, which die shortly after birth
(Adktm1/, m#2). (C) Representative PCR analysis of three
selected animals (m#1–3). (Top) The Adk wild-type allele (+/+) in
m#1 is observed as a 640 bp band, while the knockout allele (/)
in m#2 and m#3 is observed as an 840 bp band. (Bottom) The
UbiAdk transgene-specific PCR gave rise to a characteristic
amplification product of 420 bp only in m#3; the transgene was
not detectable in m#1 and m#2.
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mice. All further studies described here were therefore pur-
sued in Adktm1/-Tg(UbiAdk) mice of line Tg888.
Novel neuronal expression of ADK in
Adktm1/-Tg(UbiAdk) mouse brain
The expression pattern of ADK was analysed by immunop-
eroxidase staining performed on coronal and sagittal sec-
tions from adult Adktm1/-Tg(UbiAdk) and wild-type
mice (n = 3 per group). In wild-type coronal sections, strong
ADK immunoreactivity was detected in evenly distributed
astrocytes (Fig. 3A, C, E) whereas neurons, such as pyramidal
cells of the CA3 region (Fig. 3C) and granular neurons of the
dentate gyrus (Fig. 3E), lacked specific ADK immunoreact-
ivity. In contrast, in Adktm1/-Tg(UbiAdk) mice the dele-
tion of the endogenous Adk gene was reflected by a striking
loss of endogenous astrocytic ADK immunoreactivity, which
was replaced by rather diffuse and ubiquitous expression of
theUbiAdk transgene in both neurons and astrocytes (Fig. 3B).
Since all brain sections were stained under identical
conditions, the darker staining in the mutant sections
indicates diffuse overexpression of ADK compared with
wild type (Fig. 3A, B). While in wild-type animals ADK
immunoreactivity was nearly evenly distributed among dif-
ferent brain regions, in mutant animals ADK immunoreact-
ivity appeared to be slightly higher in cortical brain regions
compared with more basal brain regions. In the hippocampal
formation of Adktm1/-Tg(UbiAdk) brain sections,
transgene-induced neuronal expression of ADK became par-
ticularly evident in CA1 and CA3 pyramidal cells (Fig. 3B, D)
as well as in neurons of the hilus (Fig. 3F). A similar shift from
astrocytic to ubiquitous ADK immunoreactivity was observed
in the cerebellum from Adktm1/-Tg(UbiAdk) sagittal sec-
tions (data not shown). Thus, the Adktm1/-Tg(UbiAdk)
mice are characterized by novel expression of ADK in
neurons.
Fig. 2 Increased brain ADK expression and activity in Adktm1/-Tg(UbiAdk) mice. (A) Western blot analysis of aqueous protein
extracts derived from various organs from adult wild-type (wt) and Adktm1/-Tg(UbiAdk) mice (Mut). Extracts corresponding to 15 mg of
total protein each were probed with polyclonal rabbit antiserum raised against recombinant mouse ADK. Note the increase in ADK
expression in the brain of Adktm1/-Tg(UbiAdk) mice compared with wild type. (B) Brain ADK enzyme activity, as measured using an
enzyme-coupled bioluminescent assay, was increased in Adktm1/-Tg(UbiAdk) mice (n = 6) in comparison to wild-type mice (n = 7;
***P < 0.001, median test). Results are presented as relative activities and expressed as mean 6 SE. (C) EPSC traces and EPSC response
amplitudes from whole-cell recordings of CA3 hippocampal pyramidal neurons in acute slices from wild-type (n = 4) and
Adktm1/-Tg(UbiAdk) mice (n = 6), before and during application of DPCPX (200 nM). The EPSC response amplitudes were normalized to
each individual baseline. Values are expressed as the mean percentages EPSC amplitude of baseline 6 SE (**P < 0.01, Mann–Whitney test).
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Fig. 3 Photomicrographs of ADK immunoreactivity in coronal brain sections of adult mice, processed for immunoperoxidase staining
under identical conditions. (A) Coronal section of a wild-type brain hemisphere showing homogeneous distribution of individual cells
expressing ADK. (B) Transverse section of an Adktm1/-Tg(UbiAdk) brain hemisphere showing ubiquitous expression of transgenic
ADK coupled to a loss of punctate staining of endogenous ADK in individual cells. (C) CA3 region of a wild-type hippocampus
(see inset in A) at higher magnification, showing individual ADK-positive cells. (D) CA3 region (see inset in B) from an
Adktm1/-Tg(UbiAdk) mouse showing the ubiquitous expression of transgenic ADK. Note the strong ADK immunoreactivity in pyramidal
cell neurons in the Adktm1/-Tg(UbiAdk) section, which is not apparent in the wild-type section. (E) Dentate gyrus of a wild-type
hippocampus (see inset in A). Note the absence of distinct ADK staining in the granular cell layer. (F) Dentate gyrus (see inset in B) from an
Adktm1/-Tg(UbiAdk) mouse. Again, note the distinct ADK immunoreactivity in granular and hilar neurons in the Adktm1/-Tg(UbiAdk)
section, which is not apparent in the wild-type section. Scale bars: A, B, 800 mm; C, D, E, F 100 mm.
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To determine if the overexpression and novel localization
of ADK results in less ambient adenosine, activation of
A1Rs was investigated in Adktm1/-Tg(UbiAdk) mice
using in vitro electrophysiology. In wild-type brain, adenosine
exerts presynaptic inhibition in mossy fibre CA3 synapses,
primarily via activation of A1Rs (Moore et al., 2003). Because
of difficulties in performing correct local adenosine measure-
ments in brain tissue and because of large variations accord-
ing to the methods used (Delaney and Geiger, 1996), we chose
this indirect electrophysiological approach to demonstrate
ADK-dependent changes in ambient adenosine levels. We
measured EPSCs in CA3 hippocampal pyramidal neurons
of acute slices from wild-type and Adktm1/-Tg(UbiAdk)
brain in response to mossy fibre stimulation. In the presence
of picrotoxin (100 mM), seizure activity was elicited in slices
from mutant animals. To prevent the picrotoxin-induced
seizure activity, low concentrations of NBQX (an Ampa-
Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid
(AMPA) receptor antagonist) were added. We attempted
to evoke the same current amplitude from each cell; therefore,
the mean baseline amplitudes evoked from wild type cells
(n = 4, 51.63 6 26.05 pA) was not significantly different
from the mean baseline amplitude evoked from
Adktm1/-Tg(UbiAdk) cells (n = 6, 30.99 6 8.33 pA; P =
0.26, Mann–Whitney test). The effect of DPCPX, a selective
A1R antagonist, on the response was normalized according to
each individual cell’s baseline. Application of 200 nMDPCPX
resulted in an increase in the EPSC response in wild-type
mice (258 6 64%) that was significantly different from
the response in Adktm1/-Tg(UbiAdk) mice (78.8 6
6.5%; P < 0.01, Mann–Whitney test) (Fig. 2C), thus indic-
ating a reduction in ambient adenosine. In contrast, the
addition of 5 mM ITU, an inhibitor of ADK, led to a
reduction in the EPSC amplitude to 43 6 13% of baseline
values in slices taken from Adktm1/-Tg(UbiAdk) mice (n =
3), thus demonstrating the restoration of adenosine-mediated
inhibition after blockade of ADK. When DPCPX (200 nM)
was added to the ITU-inhibited slices, the EPSC amplitude
was enhanced 5-fold compared with the ITU-inhibited value
(n = 2), showing that the ITU-induced depression of the
EPSC is A1R-dependent. This set of experiments thus indic-
ates that overexpression of transgenic ADK leads to a reduc-
tion in ambient adenosine.
Spontaneous hyperlocomotion in
Adktm1/-Tg(UbiAdk) mice
To investigate the functional consequences of transgenic ADK
overexpression in the brain, we analysed spontaneous loco-
motor activity and its circadian rhythmicity on three consec-
utive days in Adktm1/-Tg(UbiAdk) and wild-type mice.
Adktm1/-Tg(UbiAdk) mice displayed heightened baseline
levels of locomotor activity per 24 h compared with wild-type
mice [F(1, 22) = 18.566, P < 0.001] (Fig. 4A). The genotype
difference was consistent over the 3-day period of recording
[F(2, 22) = 1.011, not significant]. In addition, the circadian
time-dependent changes in locomotor activity levels [F(23,
253) = 15.904, P < 0.001] were comparable in the two groups
[F(23, 253) = 0.6547, not significant] (Fig 4B), indicating that
the sleep–wake cycle, as reflected by the levels of locomo-
tion, was not affected in these mutants. Thus, the transgene-
induced ubiquitous overexpression of ADK, together
with the marked elevation in brain ADK enzyme activity,
probably plays a role in the hyperlocomotor phenotype of
Adktm1/-Tg(UbiAdk) mice.
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Fig. 4 Locomotion and circadian locomotor rhythmicity in
Adktm1/-Tg(UbiAdk). (A) The total locomotion per 24 h was
consistently enhanced in Adktm1/-Tg(UbiAdk) mice (Mut, n = 6)
compared with wild-type mice (wt, n = 7) on three consecutive
days (***P < 0.001, ANOVA). (B) The circadian rhythmicity of
locomotor activity, as expressed by relative locomotion per
hour over a 12 h light/12 h dark cycle (Zeitgeber time 0 is
according to offset of light), was similar in the two groups. Results
are expressed as mean 6 SE.
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Spontaneous and KA-induced seizure
activity in Adktm1/-Tg(UbiAdk) mice
To study the causality between ADK overexpression and
seizure activity, we analysed hippocampal and cortical
EEGs of untreated Adktm1/-Tg(UbiAdk) mice. These
revealed baseline activity similar to that of wild-type controls
(Fig. 5A, B). However, in blocks of 6-h recordings, three of
the 10 Adktm1/-Tg(UbiAdk) mice with hippocampal elec-
trodes displayed occasional seizure-like activity with a distinct
spike pattern (4 Hz) (Fig. 5C). The duration of this spike
activity ranged from 25 to 300 s. The same hippocampal
spike pattern was observed in two of the 14 mutant mice
equipped with both cortical and hippocampal electrodes.
Another 10 of these 14 mutant mice exhibited short, high-
frequency intra-ictal bursts, occurring concurrently in the
hippocampus and cortex (Fig. 5E), two of which also dis-
played longer episodes of rhythmic, high-frequency spike
activity (around 15 s) in the cortex (Fig. 5D). Each type of
spike activity occurred approximately once per hour. It is
important to note that none of these events was accompanied
by any overt sign of convulsions or muscle twitches, thus
precluding any descriptive ranking of seizures. In total,
15 out of the 24 Adktm1/-Tg(UbiAdk) mice exhibited
abnormal spiking and bursting activity in the hippocampus
and/or cortex, within a time frame of at least 6 h of recordings.
None of the wild-type animals tested in this and in previous
studies (Gouder et al., 2003, 2004) displayed similar EEG
abnormalities.
Three of the mutants that displayed recurrent episodes
of seizure-like spike activity in the hippocampus and cortex
were tested for responsiveness to the ADK inhibitor ITU
[3.1 mg/kg i.p. (50% of ED50)] (Wiesner et al., 1999;
Gouder et al., 2004). Since these mutants do not express
endogenous ADK, we were able to inhibit specifically the
transgene-induced ubiquitously expressed ADK. Thirty min-
utes after ITU injection, abnormal bursts and seizure-like
spike activity were completely abolished (data not shown).
Thus, the transgenic overexpressionofADK leads tooccasional
episodes of spontaneous seizure-like spike activity as well as
abnormal bursting, which can be suppressed by inhibiting
the transgenic ADK.
To investigate the consequences of constitutive ADK over-
expression in an established model of temporal lobe epilepsy,
we studied the EEG and histological changes following an
intrahippocampal KA injection in Adktm1/-Tg(UbiAdk)
and wild-type mice. Untreated mice (n = 3 per genotype)
served as controls. Daily analysis of intrahippocampal EEG
recordings during the first 6 weeks after KA injection showed
Fig. 5 Representative EEG activities from untreated and KA-injected mice. (A, B) Normal theta activity recorded in untreated wild-type
(wt, A) and Adktm1/-Tg(UbiAdk) (Mut, B) mice. (C, D, E) Representative abnormal activity occasionally observed in untreated
Adktm1/-Tg(UbiAdk) mice. (C) Seizures observed in hippocampus (Hip) and (D) cortex (Ctx). (E) Abnormal bursting observed in both
hippocampus and cortex. (F, G) Seizure activity observed 4 weeks after KA injection in wild-type (wt, F) and Adktm1/-Tg(UbiAdk)
(Mut, G) mice. Note the increased intra-seizure spike frequency in KA-treated Adktm1/-Tg(UbiAdk) mice compared with KA-treated
wild-type mice.
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that both Adktm1/-Tg(UbiAdk) mice and wild-type mice
developed recurrent electrographic seizure activity after a
2-week latent phase. It is important to note that this recurrent
partial seizure activity is accompanied neither by convulsions
nor by any other behavioural manifestations. Therefore, the
analysis of seizure activity is limited to electrographic para-
meters. Recordings taken between 4 and 6 weeks after KA
injection revealed both similarities and differences between
the genotypes. The number of seizures per hour was similar
in the two groups and the mean duration of the seizures
was slightly but not significantly increased in Adktm1/-
Tg(UbiAdk) mice compared with wild-type seizure duration
(Table 1). However, Adktm1/-Tg (UbiAdk) mice were
characterized by a significant increase in intra-ictal spike fre-
quency (P < 0.01, compared with wild-type; Mann–Whitney
test) (Fig. 5F, G; Table 1). An acute treatment with ITU
(3.1 mg/kg, i.p.) was equally effective in suppressing seizure
activity in the two groups (data not shown). The constitutive
overexpression of ADK in Adktm1/-Tg(UbiAdk) mice is
thus associated with an increased intra-ictal spike frequency,
once epilepsy is established.
Epileptic hippocampus in
Adktm1/-Tg(UbiAdk) mice does not
display upregulation of astrocytic ADK
The gross histological analysis of cresyl violet-stained
hippocampal sections taken 6 weeks after KA injection of
Adktm1/-Tg(UbiAdk) and wild-type mice (n = 6 animals
per genotype, n = 6 slices per animal) revealed two charac-
teristic features of our mouse model of KA-induced epilep-
togenesis: (i) in both genotypes a characteristic neuronal loss
became evident in the epileptic hippocampus, notably affect-
ing the CA1 and hilus regions; and (ii) granule cell dispersion,
a characteristic hallmark of KA-induced epileptogenesis,
became apparent in both genotypes (Fig. 6A, B). However,
clear differences between wild-type and Adktm1/-
Tg(UbiAdk) mice were observed in brain sections stained
for ADK immunoreactivity. The wild-type epileptic hippo-
campus contained a high number of ADK-positive reactive
astrocytes (Fig. 6C, E). This was not the case in the epileptic
hippocampus of Adktm1/-Tg(UbiAdk) mice (Fig. 6D, F)
which is consistent with the genetic disruption of the endo-
genous astrocytic ADK in these transgenic animals. In addi-
tion, in Adktm1/-Tg(UbiAdk) mice, the KA-induced loss of
CA1 and CA3 pyramidal cells resulted in a decrease in ADK
immunoreactive neurons (Fig. 6D) compared with the num-
ber seen in untreated Adktm1/-Tg(UbiAdk) hippocampus
(Fig. 3B). Thus, the intrahippocampal injection of KA in
Adktm1/-Tg(UbiAdk) mice leads to recurrent seizure activ-
ity in the absence of endogenous astrocytic upregulation
of ADK.
To determine if the development of astrogliosis is affected
by the lack of KA-induced overexpression of astrocytic ADK,
gliosis was examined using GFAP immunofluorescence
staining. GFAP immunostaining of non-treated Adktm1/-
Tg(UbiAdk) and wild-type mice (n = 6 animals per genotype,
n = 6 slices per animal) showed a similar distribution of
astrocytes (Fig. 7A, C). In contrast, 6 weeks after KA injection
astrogliosis had developed in both genotypes (Fig. 7B, D) and
was essentially comparable to our previous work (Gouder
et al., 2004). Thus, in the absence of endogenous astrocytic
ADK, Adktm1/-Tg(UbiAdk) mice develop KA-induced
astrogliosis. Therefore, we conclude that KA-induced astro-
cytic upregulation of ADK in wild-type mice is a consequence
of astrogliosis.
Discussion
In the present investigation we describe the novel mouse line
Adktm1/-Tg(UbiAdk), which constitutes genetic rescue of
the lethal deficiency of ADK (Boison et al., 2002). The rescue
was achieved by introducing an Adk transgene (Fig. 1), which
resulted in the ubiquitous expression of the short brain-
specific isoform (38.7 kDa) of ADK (McNally et al., 1997)
(Fig. 2A). In contrast, a liver-specific transgene failed to pro-
vide genetic rescue of the lethal ADK deficiency (L. Scheurer,
T. Ru¨licke and D. Boison unpublished data). This finding,
together with our current finding of low reconstitution of
ADK in the liver of Adktm1/-Tg(UbiAdk) mice (Fig. 2A),
indicates that the early postnatal lethality seen in Adktm1/
mice may be due to a liver-independent phenomenon. Thus,
the ubiquitous expression of the short isoform of ADK was
sufficient and necessary to restore vital physiological func-
tions on an ADK-deficient background.
In addition to diffuse, ubiquitous overexpression of brain
ADK, which is also reflected by a marked increase in total
brain ADK enzyme activity (Fig. 2B), Adktm1/-Tg(UbiAdk)
mice display novel ectopic neuronal expression of ADK.
They lack the native ADK gene and therefore endogenous
Table 1 EEG activity in wild-type and Adktm1/-
Tg(UbiAdk) 4–6 weeks after kainic acid injection
Strain No. of
seizures
per hour
Mean
seizure
duration
Mean
intra-ictal spike
frequency
(s) (Hz)
Wild type 23.17 6 5.56 44.2 6 5.3 4.00 6 0.28
(n = 6) (n = 6) (n = 6)
Adktm1/-
Tg(UbiAdk)
21.00 6 7.40
(n = 6)
66.7 6 28.5
(n = 6)
8.50 6 0.74**
(n = 6)
The total number of seizures was counted during a representative
hour of recording with minimal background noise. The duration
of each of these seizures during the representative hour of
recording was measured in seconds and averaged for each mouse.
For the mean intra-ictal spike frequency, the frequency of spikes
during 10 s of five representative seizures was counted and
averaged for each mouse. Results are mean 6 SD for seizure
duration and mean 6 SE for all other values (**P < 0.01,
Mann–Whitney test).
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astrocytic ADK expression is no longer observed. Thus,
Adktm1/-Tg(UbiAdk) mice provide for the first time the
opportunity to study adenosine-mediated neuromodulation
in the absence of endogenous astrocytic ADK expression. In
addition, the novel neuronal expression of ADK may change
adenosine levels in synaptic microenvironments, thus affect-
ing presynaptic inhibition in the hippocampus more directly.
Therefore, hippocampi from Adktm1/-Tg(UbiAdk) mice
are expected to be affected by enhanced neuronal excitability.
The changes of ADK expression in Adktm1/-Tg(UbiAdk)
mice, both in cell-type specificity as well as in quantity, are
likely to affect the excitability of the brain via altered aden-
osine levels. Brain adenosine levels, as such, are difficult to
elucidate, given the fluctuations of adenosine release in
response to tissue trauma and the death of the animal
(Delaney and Geiger, 1996). Therefore, we investigated the
functional effects of ambient adenosine on activation of A1Rs
from the mossy fibre synapses on CA3 pyramidal neurons.
Several studies have shown a positive relationship between the
pharmacological manipulation of extracellular adenosine and
alterations in presynaptic inhibition in the hippocampus (Pak
et al., 1994; Moore et al., 2003). In addition, an absence of
adenosine-mediated inhibition of excitatory glutamatergic
neurotransmission has been observed in adenosine A1R
knockout mice (Johansson et al., 2001; Fredholm et al.,
2005). Accordingly, the picrotoxin-induced seizure activity
in slices from Adktm1/-Tg(UbiAdk) mice, as well as the
lack of EPSC response due to the pharmacological blockade
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Fig. 6 Changes in hippocampal cytoarchitecture and ADK immunoreactivity 6 weeks after an intrahippocampal kainic acid injection.
Representative sections taking into account variation among animals (n = 6 animals per genotype). (A, B) Cresyl violet staining of coronal
sections through brains of wild-type (A) and Adktm1/-Tg(UbiAdk) mice (B). Both genotypes developed a characteristic KA-lesion
including loss of neurons in the CA1 and hilus regions and granule cell dispersion in the dentate gyrus. (C, D) ADK immunoreactivity of
coronal sections through brains of wild-type (C) and Adktm1/-Tg(UbiAdk) mice (D). (E, F) Insets in C and D at higher magnification.
Note the lack of KA-induced overexpression of ADK in the mutants. The location of the bipolar intrahippocampal electrode is indicated
with an asterisk (*). Scale bar: A, B, C, D, 500 mm; E, F, 100 mm.
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of A1R in mossy fibre CA3 synapses from Adktm1/-
Tg(UbiAdk) mice, is consistent with a reduction in hippo-
campal adenosine levels. Concordantly, A1R-dependent
adenosine-mediated inhibition of the EPSC amplitude
could be restored by inhibition of ADK. The overexpression
of ADK is ubiquitous, affecting all brain regions in
Adktm1/-Tg(UbiAdk) mice; therefore, they probably
display an overall decrease in adenosinergic tone due to the
increased ADK enzyme activity. The resulting lack of aden-
osinergic inhibition throughout the brain is manifested
behaviourally by a marked increase in locomotor activity
baselines without alteration of the circadian locomotor
rhythm (Fig. 4). This observation is in line with the well-
documented motor stimulant properties of adenosine recep-
tor antagonists (Popoli et al., 1998; Svenningsson et al., 1999).
A 1.8-fold hippocampal overexpression of ADK, confined
to hypertrophied astrocytes, has been associated with astro-
gliosis and recurrent seizure activity in the mouse kainate
model of temporal lobe epilepsy (Gouder et al., 2004).
Because Adktm1/-Tg(UbiAdk) mice display constitutive
expression of ADK in both neurons and astrocytes in the
absence of endogenous astrocytic ADK, these mutants pro-
vide an ideal tool to study the causal relationship between
astrocytic overexpression of ADK, astrogliosis and seizure
activity. The transgene-induced overexpression of ADK in
Adktm1/-Tg(UbiAdk) mice correlates with an increase in
ADK activity (2.2-fold compared with control, Fig. 2B) com-
parable to the increase in ADK activity in epileptic, KA-
treated wild-type mice. This increase in ADK activity resulted
in recurrent episodes of high frequency spike activity in
about two-thirds of untreated Adktm1/-Tg(UbiAdk)
mice (Fig. 5C–E). This electrographic spike activity mimicked
closely the electrographic seizures recorded in the mouse
kainate model of epilepsy (Fig. 5F) and was not accompanied
by convulsions or muscle twitches, thus precluding any
descriptive ranking of seizures. However, treatment of
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Fig. 7 GFAP immunofluorescence in representative sections from non-treated and KA-treated Adktm1/-Tg(UbiAdk) and wild-type mice
(n = 6 animals per genotype). Transverse brain sections from mice taken 6 weeks after KA injection and those from naive control
animals were stained for the astrocyte marker GFAP. Optical sections were digitized at high magnification. (A, B) Dentate gyrus of a
non-treated wild type mouse (A) compared with the same region of a KA-treated wild type mouse (B) shows the typical enlargement of
astrocytic cell bodies in response to KA. (C, D) Dentate gyrus of a naive Adktm1/-Tg(UbiAdk) mouse (A) compared with the same region
of a KA-treated Adktm1/-Tg(UbiAdk) mouse demonstrates the development of astrogliosis in the absence of endogenous astrocytic
ADK. sg = stratum granulosum; hi = hilus. Scale bar: 50 mm.
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Adktm1/-Tg(UbiAdk) mice displaying seizure-like spike
activity with ITU allowed the inhibition of the transgenic
ADK, which effectively suppressed the abnormal spiking
activity. This shows that the overexpression of ADK is res-
ponsible for the electrographic seizure-like activity observed
in mutant mice, and when adenosine levels are reconstituted
by inhibition of ADK the brain resumes a normal firing pat-
tern. These data suggest that overexpression of ADK, and the
subsequent decrease in adenosinergic tone, is a cause of
seizure activity. This assertion is supported by other studies
which showed that decreased protective adenosine levels are
likely to result in a lower threshold for seizure induction
(Etherington and Frenguelli, 2004). Also, adenosine receptor
antagonists can elicit seizures in the hippocampal CA3 area
(Dunwiddie, 1999), prolong epileptic seizures (Dragunow
and Robertson, 1987) or convert recurrent seizure activity
into status epilepticus (Young and Dragunow, 1994).
In addition, the cell-type-specific expression pattern of
ADK and its endogenous gene regulation may play a crucial
role in astrogliosis. It is important to note that, in contrast to
endogenous ADK, which is upregulated in parallel to astrogli-
osis and seizure activity, the transgenic ADK appears to
be constitutively expressed at high levels; 6 weeks after
intrahippocampal KA injection, Adktm1/-Tg(UbiAdk)
mice showed no sign of epilepsy-associated upregulation
of ADK (Fig. 6 D, F). We have recently proposed that
the gradual increase in astrocytic ADK expression in
KA-treated wild-type mice may contribute to epileptogenesis
(Gouder et al., 2004). However, from this previous study,
we could not determine whether overexpression of ADK in
the epileptic hippocampus was a cause or a consequence of
astrogliosis or seizure activity. The occurrence of astrogliosis
in the absence of endogenous astrocytic ADK, as observed in
KA-injected Adktm1/-Tg(UbiAdk) mice (Figs 5 and 6),
clearly demonstrates that the overexpression of ADK in the
epileptic hippocampus is a consequence of astrogliosis.
The reactive overexpression of ADK after KA-induced
gliosis and seizure activity might be explained as a compens-
atory mechanism. The initial injection of KA into the hippo-
campus would cause immediate excitotoxic neuronal death
and status epilepticus, triggering endogenous protective
mechanisms, including the release of adenosine (During
and Spencer, 1992). Continued cell death, astrogliosis and
reorganization of the hippocampus during development of
chronic epilepsy occur while ADK expression is increasing to
abnormally high levels (Gouder et al., 2004). This increase in
ADK expression may also provide a salvage route for the
adenine nucleotides needed to sustain nucleic acid synthesis
during reorganization of the hippocampus. Since it is known
that adenosine accumulates during seizure activity, it is
conceivable that the chronic release of adenosine during
the epileptic state continues to reinforce the overexpression
of ADK in astrogliotic tissue. The effect of overexpressed ADK
may be further aggravated by decreased activity of A1Rs, as
has been demonstrated in the hippocampus of kindled rats
(Rebola et al., 2003). Thus, a vicious circle can be envisaged in
that, through overexpression of ADK and reduction of A1Rs,
the threshold for seizure induction during interictal periods
is reduced, thereby contributing to the progressive course of
chronic epilepsy. This hypothesis is supported by our finding
that KA-injected Adktm1/-Tg(UbiAdk) mice display a sig-
nificantly increased intra-seizure frequency of discharges
as well as a trend towards longer seizure duration compared
with KA-injected wild-type mice. These findings indicate that,
once epilepsy is fully established, the constitutive transgenic
overexpression of ADK and the novel neuronal expression
of the enzyme may further increase seizure activity. On the
other hand, the number of seizures per hour in KA-injected
Adktm1/-Tg(UbiAdk) mice was not changed compared
with controls. This finding could indicate that the lack of
astrocytic upregulation of ADK in KA-injected mutants pre-
vents a further decline in protective adenosine levels, thus
protecting the animals from an increase in seizure numbers.
In summary, we have shown that overexpression of brain
ADK on its own can lead to seizure activity. In addition, in the
KA model of temporal lobe epilepsy, overexpression of ADK
is a consequence of astrogliosis. Thus, astrogliosis-induced
overexpression of ADK in the KA model most likely leads
to the perpetuation of chronic seizure activity.
This study clearly demonstrates that dysregulation of the
adenosinergic system via a change in the expression pattern
of ADK is linked to seizure activity. Therefore, epilepsy-
associated overexpression of ADK provides a rationale for
therapeutic intervention. The notion that an imbalance of
adenosinergic signalling contributes to seizure activity and
could be a therapeutic target is supported by the fact that
drugs which augment the adenosine response, e.g. ADK inhib-
itors (Wiesner et al., 1999; Kowaluk and Jarvis, 2000; Gouder
et al., 2004; McGaraughty et al., 2005), adenosine receptor
agonists (von Lubitz et al., 1993; De Sarro et al., 1999; Gouder
et al., 2003) and intraventricular adenosine (Boison et al.,
1999), suppress seizures. Here, the adenosinergic imbalance
in Adktm1/-Tg(UbiAdk) mice, which resulted in spontan-
eous seizures and exacerbation of KA-induced seizures, was
able to be treated by ADK inhibition, providing further
evidence that adenosinergic therapy would be beneficial
for the treatment of epilepsy. Because of peripheral side-
effects of adenosine (Dunwiddie, 1999), effective strategies
that enhance the protective effects of adenosine in an area
of adenosinergic dysfunction (i.e. a seizure focus) may require
a novel approach, such as the local delivery of adenosine by
cellular implants. This approach has proven successful in the
rat kindling model of epilepsy (Huber et al., 2001). Thus,
future work should focus on therapeutic cellular implants
releasing adenosine in the vicinity of an epileptic lesion,
where ADK is overexpressed. By locally reconstituting the
inhibitory adenosinergic tone, it is expected that seizure
activity would be suppressed.
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